Journal
IMMUNOTHERAPY
Volume 13, Issue 3, Pages 185-188Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0247
Keywords
alpha-gal; covid-19; glycan; immunity; microbiota; pandemic; probiotic; SARS-CoV-2; tick; vaccine
Categories
Funding
- Consejeria de Educacion, Cultura y Deportes, JCCM, Spain [CCM17-PIC-036, SBPLY/17/180501/000185]
Ask authors/readers for more resources
Enhancing the immune response to alpha-Gal could contribute not only to controlling COVID-19, but also to providing broader immunity that may help prevent reinfections by SARS-CoV-2-related genetic variants or other pathogens that impact individual responses to SARS-CoV-2.
Despite the advances and potential impact that new vaccines represent for the prevention and control of COVID-19, interventions boosting the immune response to alpha-Gal with a broader and not pathogen-specific immunity may contribute not only to the control of COVID-19 but also to potential re-infections by SARS-CoV-2-related genetic variants or other pathogens that negatively affect the individual response to SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
